Zolendronic Acid

DRUG4 trials

Sponsors

Wales Cancer Trials Unit, Novartis Pharmaceuticals, Children's Cancer Hospital Egypt 57357, Prince of Wales Hospital, Shatin, Hong Kong

Conditions

Breast CancerBreast NeoplasmsHypercalcemia of MalignancyMetastatic CancerOsteoporosisSarcopenia in Elderly

Phase 3

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

Wales Cancer Trials UnitBreast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer

Start: 2006-01-31End: 2015-10-31Updated: 2013-03-13

Zometa Study in Pediatric Acute Lymphoblastic Leukemia

CompletedNCT01656512

Children's Cancer Hospital Egypt 57357Osteoporosis

Start: 2011-10-31End: 2015-08-31Updated: 2018-04-17

Phase 4

Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer

TerminatedNCT00375752

Novartis PharmaceuticalsBreast Neoplasms

Start: 2006-06-01End: 2010-12-16Updated: 2017-06-26

RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis

RecruitingNCT06643780

Prince of Wales Hospital, Shatin, Hong KongSarcopenia in Elderly

Start: 2024-04-09End: 2027-10-31Target: 120Updated: 2024-10-16

Related Papers

RANK-ligand inhibition to combat sarcopenia with underlying osteoporosis: a study protocol for a randomized, double-blind, double-dummy, active-controlled trial.

2025-08-04

The use of randomisation-based efficacy estimators in non-inferiority trials.

2017-03-093 citations

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.

2013-12-1170 citations